UCB’s Rystiggo Approved in China for Generalized Myasthenia Gravis
Belgium-based biopharma UCB (EBR: UCB) announced that it has received marketing approval from China‘’s National...
Fineline Cube
Renji Hospital Partners with Raffles Medical Group to Boost Shanghai’s Medical Tourism
Renji Hospital, a comprehensive Class 3A hospital established in 1844 in Shanghai, has partnered with...
AstraZeneca and Daiichi Sankyo Initiate DESTINY-Gastric05 Study for Enhertu in Metastatic Gastric Cancer
Partners AstraZeneca (NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) announced the first patient dosing in...
China Proposes New Measures to Optimize High-End Medical Device Regulation
The National Medical Products Administration (NMPA) has released the “Measures for Optimizing Full Lifecycle Supervision...
GE Healthcare Takes Full Ownership of Japan’s Nihon Medi-Physics
US medical device and life sciences giant GE Healthcare Technologies Inc., (NASDAQ: GEHC) announced that...
Hengrui Pharmaceuticals’ Ivarmacitinib Approved for Rheumatoid Arthritis in China
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received additional indication approval...
Chinese Firms Nanjing F&S and Hunan Huize Form Alliance for Full-Process Pharma Services
Chinese companies Nanjing F&S Pharmatech Co., Ltd and Hunan Huize Biopharmaceutical Technology Co., Ltd, a...
Huapont Life Sciences Gains NMPA Approval for Generic Daivobet
China-based Huapont Life Sciences Co., Ltd (SHE: 002004) announced that it has received marketing approval...
Chinese IVD Firm Annoroad Gene Targets Global Expansion with IPO
China-based Annoroad Gene Technology (Beijing) Co., Ltd. has submitted an initial public offering (IPO) filing...
Ascletis Pharma’s ASC30 Shows Positive Results in US Phase Ib Obesity Study
China-based Ascletis Pharma Inc. (HKG: 1672) announced positive interim results from a Phase Ib study...
Abbisko Therapeutics Secures $85M from Merck for Pimicotinib Global Rights
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) announced that its German partner Merck KGaA...
Chia Tai Tianqing Launches NPP for Urgent Cancer Treatment in Hong Kong
China-based Chia Tai Tianqing Pharmaceutical has entered into a Named Patient Program (NPP) collaboration with...
Innovent Biologics’ IBI363 Granted Breakthrough Therapy Designation for Melanoma
China-based Innovent Biologics, Inc. (HKG: 1801) announced that it has received breakthrough therapy designation (BTD)...
NHC Data Reveals Digital Leap for Class 3 Hospitals Amid Drug Cost Crackdown
China’s 2,168 Class 3 public hospitals demonstrated enhanced fiscal discipline in 2023, with medical services...
Hengrui’s HRS-5965 Granted Breakthrough Therapy Designation for IgA Nephropathy
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received breakthrough therapy...
Sanofi’s Dupixent Approved in Japan for Chronic Obstructive Pulmonary Disease
Sanofi (EPA: SAN, NASDAQ: SNY) announced that it has received approval from Japan’s Ministry of...
Pacific Shuanglin Bio-pharmacy Partners with XtalPi for Blood Product Innovation
China-based Pacific Shuanglin Bio-pharmacy Co., Ltd (SHE: 000403) has formed a strategic partnership with Shenzhen-based...
Novartis’ Pluvicto Gains Expanded FDA Approval for Prostate Cancer Treatment
Swiss pharmaceutical giant Novartis (NYSE: NVS) announced that it has received expanded indication approval from...
EMA’s CHMP Issues Negative Opinion on Lilly’s Kisunla for Alzheimer’s
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...
China’s IAC Drafts Commercial Health Insurance Drug List A-Series to Bridge NRDL Coverage Gaps
The Insurance Association of China (IAC) has unveiled its inaugural draft for the Commercial Health...